T3D Therapeutics announced the appointment of Charles Lineberry, Ph.D. and Barry Buzogany, Esq. to its Board of Directors.
Dr. Lineberry, founder and president of Lineberry Research Associates, has a Ph.D. in physiological psychology, NIH post-doctoral training in neurobiology, and 22 years of professional experience in biomedical research, including 18 years in clinical drug development for the pharmaceutical industry. Dr. Lineberry oversees the preparation of INDs, NDAs and final study reports, and other clinical and regulatory projects. Prior to the founding of Lineberry Research Associates, Dr. Lineberry was Senior Director of Clinical Neurosciences at Burroughs Wellcome Co., where he directed the efforts of 60 individuals and was responsible for the development of compounds in the therapeutic areas of psychiatry, neurology and anesthesiology. Under his leadership, his staff was responsible for the submission of 18 INDs and 7 approved NDAs. His experience includes both domestic and international drug development, and he has held teaching and research positions in the medical schools at the University of Florida in Gainesville and the University of Pittsburgh.
Mr. Buzogany is an accomplished C-level executive (CEO/COO/CLO) for the past 25 years with both public and private companies, ranging in size from early stage to multinationals. He has a record of high achievement at each of the pharmaceutical, medtech, life sciences, and contract research organizations that he has served. He has held executive positions at Battelle Memorial Institute, Boehringer Ingelheim Pharma, Centocor, and Gene Logic. Recent past companies include Icoria, Inc. (formerly Paradigm Genetics), a publicly traded biotech where he served as VP, General Counsel and Board Secretary before being named Chief Operating Officer; and Jenken Biosciences, Inc., an early stage drug development company where he was President and CEO for three and a half years. He currently serves as business, legal and board-level advisor and mentor to several healthcare-related technology companies.